[{"orgOrder":0,"company":"Gaelic Laboratories","sponsor":"Athlone Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2025","type":"Acquisition","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gaelic Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gaelic Laboratories \/ Gaelic Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Gaelic Laboratories \/ Gaelic Laboratories"}]

Find Clinical Drug Pipeline Developments & Deals by Gaelic Laboratories

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : Through the acquisition of Amoxicillin, an antibiotic targeting bacterial penicillin-binding protein, the deal aims to advance treatment for antibiotic-resistant infections.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          December 11, 2025

                          Lead Product(s) : Amoxicillin Trihydrate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Athlone Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank